The systemic treatment of lung cancer has revolutionized. New targeted treatment options have driven us to consider more specific subpopulations of lung cancer. For example, epidermal growth factor receptor (EGFR) inhibitors emerged as more effective in EGFR mutant patients. Crizotinib arose as a potent alternative in patients with ALK translocation. Histopathological subtypes and other predictive markers may also affect the treatment choice due to differences in the pharmacokinetics, pharmacodynamics, and therapeutic targets. As a result, lung cancer treatment has moved from a broad empirical viewpoint to a more personalized approach. In the near future, new targeted agents are likely to provide more specialized treatment options for patient.
Introduction
Lung cancer is the leading cause of cancer related death worldwide. Due to the difference in their management, lung cancer has historically been classified on histological basis as small (SCLC) and non-small cell (NSCLC) lung cancer. Today, however, we are increasingly more focused on new treatment options targeting specific subpopulations of lung cancer. In this review, we aimed to discuss the latest treatment approaches with a particular interest in individualized therapies and the specific targets for lung cancer.
Histopathology in treatment choice
In the pre-targeted therapy era, histopathology was not a predictive factor in the treatment of NSCLC. The combination therapies of platin vinca alkaloid, paclitaxel, docetaxel or gemcitabine with platinum agents have shown similar efficacy in different NSCLC histology (1) . Today, however, the differences in the efficiency of some newly found chemotherapeutic agents and targeted therapy are well recognized. This condition has led to a tendency towards a more personalized therapy rather than the established empirical therapy.
Histopathological subtypes and other predictive markers may, indeed, affect the treatment choice due to the differences in pharmacokinetics, pharmacodynamics, and therapeutic targets. It is well accepted that the treatment approach for a 70 year-old smoking man, diagnosed as squamous cell carcinoma (SqCC) of the lung, would differ from that of a 40 year-old non-smoker woman diagnosed as adenocarcinoma of the lung. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations, which are among the predictive factors of targeted therapy, occur more frequently in adenocarcinoma of the lung in non-smoker Asian patients.
Pemetrexed, a pyrolpyrimidine antifolate analog, is a good example of explaining the predictive value of histology. Pemetrexed is more effective in non-squamous histology than in SqCC (2-4). It demonstrates its mechanism of action through the inhibition of the thymidylate synthetase enzyme. Gen microarray studies have previously demonstrated that thymidylate synthetase gene expression was higher in SCLC and SqCC tumor tissues (5) . Thymidylate synthetase mRNA levels have also been also found higher in SqCC patients than in adenocarcinoma patients (6) . Pemetrexed is considered to be ineffective in SqCC due to the high level of thymidylate synthetase. Thus, it has been recommend-ed in non-squamous NSCLC patients.
Bevacizumab, a monoclonal antibody of the vascular endothelial growth factor, has been used in the treatment of glial tumors, renal cell, and colorectal carcinomas. Bevacizumab has also proven efficacy in the induction and maintenance treatment of NSCLC (7). A randomized phase II study showed that the median time to disease progression was significantly longer with bevacizumab in NSCLC patients. However, lifethreatening pulmonary hemorrhage occurred in 6 patients, four of which eventually died due to fatal complications. Serious hemorrhagic side effects were more common among patients with squamous-cell carcinomas (8), a finding which is explained by the central and cavitary presentation of SqCC lesions. Taken together, bevacizumab has been recommended in non-squamous NSCLC, but not in SqCC patients.
Other predictive factors
Cetuximab, an EGFR inhibitor, is a chimeric (mouse/ human) monoclonal antibody, used in both the treatment of metastatic colorectal and head and neck cancer. It is also effective in the systemic treatment of NSCLC. The FLEX study included EGFR positive NSCLC patients and the addition of cetuximab to cisplatin-vinorelbine chemotherapy achieved longer survival rates (9) . Immunohistochemical scoring revealed that this benefit was higher in patients with high EGFR expression. Additionally, cetuximab displayed longer survival in high-EGFR-expression SqCCs.
Cisplatin and carboplatin, which are platinum agents, display their anticancer effect via DNA adduct formation. The excision repair cross-complementation group 1 (ERCC1) is a member of nucleotide excision repair system. It plays a role in repair of platinum induced DNA adducts and causes platinum resistance (10) . A study showed a relation of ERCC1 in NSCLC patients receiving gemcitabine plus carboplatin chemotherapy. The difference in the response rate to chemotherapy, in the median survival time and in the 1-year survival rate between patients with low ERCC1 expression levels in tumor tissues and those with high ERCC1 expression levels was significant (11) . The MADcIT study assessed the efficiency of NSCLC treatment depending on ERCC1 levels. Cisplatin-based chemotherapy was administered to patients with low ERCC1 expression and was compared with patients with high ERCC1 expression who did not receive chemotherapy. Eventually, a median of 6.6 months of progression free survival (PFS) and 13.3 months of overall survival (OS) was obtained with this protocol (12) . A phase III trial is currently ongoing with a similar design.
The ribonucleotide reductase M1 enzyme (RRM1) is essential for the production of deoxyribonucleotides prior to DNA synthesis in S phase of dividing cells and is also fundamental to nucleotide metabolism. RRM1 is the dominant molecular determinant of gemcitabine efficacy (13). Zhang GB et al. showed that the response rate to chemotherapy and survival rates were more favorable in patients with low RRM1 expression levels in tumor tissues (11) . In the MADcIT study, patients with low RRM1 expression levels received adjuvant gemcitabine, but doublet regimen without gemcitabine was given to patients with high RRM1 expression levels and the authors reported long survival rates (12) .
Tyrosine kinase inhibitors
Gefitinib and erlotinib, which are EGFR tyrosine kinase inhibitors, are effective in the treatment of NSCLC. The effectiveness has been shown to be higher in the adenocarcinoma of non-smoker Asian women, in whom, EGFR mutations has been previously shown to occur more frequently. Moreover, EGFR mutations are found in gefitinib responder lung cancer patients (14, 15) . In the IPASS study, paclitaxel and carboplatin combination were compared to gefitinib in non-smoker adenocarcinoma patients (16) . Gefitinib treatment was more effective than chemotherapy in EGFR mutant, but not wild type, patients. Accordingly, EGFR kinase inhibitors have been studied more in patients with EGFR mutation. The Asian studies suggest gefitinib superiority in EGFR mutant patients (17) (18) (19) . EURTAC trial included patients with EGFR gene exon 19 deletion or exon 21 L858R mutation (20) . They aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of NSCLC. Median PFS was longer in erlotinib group. KRAS mutation is also predictive in the treatment of EGFR tyrosine kinase inhibitors. Response of erlotinib or gefitinib is worst in KRAS mutant NSCLC patients (21) (22) (23) .
ALK inhibitors
EML4-ALK fusion gene was described in NSCLC tumor tissue in 2007 (24) . This product of EML4-ALK translocation has been found in 4% of NSCLC and occur more frequently (20%) in adenocarcinoma, young, and nonsmoker patients. ALK rearrangement rarely overlaps with EGFR and KRAS mutations. Crizotinib is an ALK and ROS1 (c-ros oncogene1) receptor tyrosine kinase inhibitor. A long survival rate has been achieved with crizotinib treatment in ALK-Positive NSCLC patients (1-yr OS: 74%; 2-yr OS: 54%) (25) .
MET gene as a target of treatment
c-Met (MET or MNNG HOS Transforming gene) is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR). MET expression is associated with a worse prognosis in many cancers including NSCLC. MET activation is implicated in the resistance to erlotinib/gefitinib in patients with activating EGFR mutations. Spiegel et al. reported a study about onartuzumab (MetMAb), a monoclonal antibody to HGFR in 2012 ASCO meeting. They investigated onartuzumab as a second line treatment for NSCLC in phase II OAM4558g trial. Although minimal effectiveness was detected in the whole NSCLC population, onartuzumab treatment achieved a longer PFS and OS in MET positive patients.
Conclusion
As a result, lung cancer treatment has moved from a broad empirical viewpoint to a more personalized approach. In the near future, new targeted agents are likely to provide more specialized treatment options for patient.
